[1]
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein, Textbook of Diabetes. John Wiley & Sons, Incorporated, 2016 [Online]. Available: https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056&query=#
[2]
S. Gururaj Setty, W. Crasto, J. Jarvis, K. Khunti, and M. J. Davies, ‘New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes’, Postgraduate Medical Journal, vol. 92, no. 1085, pp. 152–164, Mar. 2016, doi: 10.1136/postgradmedj-2015-133716.
[3]
H. Daly et al., ‘Development of a self-management education module for those with type 2 diabetes on injectable therapies’, Practical Diabetes, vol. 32, no. 8, pp. 305–310a, Oct. 2015, doi: 10.1002/pdi.1979.
[4]
Ajikumar B Aryangat and John E Gerich, ‘Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk’, Vascular Health and Risk Management, vol. 6, 2010 [Online]. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860446/
[5]
S. G. Ashwell et al., ‘Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes’, Diabetic Medicine, vol. 23, no. 3, pp. 285–292, Mar. 2006, doi: 10.1111/j.1464-5491.2005.01781.x.
[6]
R. G. Bretzel, U. Nuber, W. Landgraf, D. R. Owens, C. Bradley, and T. Linn, ‘Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial’, The Lancet, vol. 371, no. 9618, pp. 1073–1084, Mar. 2008, doi: 10.1016/S0140-6736(08)60485-7.
[7]
C. Carver, ‘Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes’, The Diabetes Educator, vol. 32, no. 6, pp. 910–917, Nov. 2006, doi: 10.1177/0145721706294259.
[8]
Sharon Allard,Caroline Butler,Sue Cradock,Heather Daly,Jemma Edwards,Elizabeth Gilbert, ‘Using Conversation Maps in practice: the UK experience’, Journal of Diabetes Nursing, vol. 14, no. 1, 2010 [Online]. Available: http://go.galegroup.com/ps/i.do?id=GALE|A245106172&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=fe5329820c5da4ed2dd0a88a5ced5962
[9]
M. J. Davies, R. Donnelly, A. H. Barnett, S. Jones, C. Nicolay, and A. Kilcoyne, ‘Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study’, Diabetes, Obesity and Metabolism, vol. 11, no. 12, pp. 1153–1162, Dec. 2009, doi: 10.1111/j.1463-1326.2009.01154.x.
[10]
M. J. Davies, R. Donnelly, A. H. Barnett, S. Jones, C. Nicolay, and A. Kilcoyne, ‘Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study’, Diabetes, Obesity and Metabolism, vol. 11, no. 12, pp. 1153–1162, Dec. 2009, doi: 10.1111/j.1463-1326.2009.01154.x.
[11]
M. M. Funnell, ‘Overcoming Barriers to the Initiation of Insulin Therapy’, Clinical Diabetes, vol. 25, no. 1, pp. 36–38, Jan. 2007, doi: 10.2337/diaclin.25.1.36.
[12]
A. J. Garber et al., ‘Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)’, Diabetes, Obesity and Metabolism, vol. 8, no. 1, pp. 58–66, Jan. 2006, doi: 10.1111/j.1463-1326.2005.00563.x.
[13]
S. C. L. Gough, ‘A review of human and analogue insulin trials’, Diabetes Research and Clinical Practice, vol. 77, no. 1, pp. 1–15, Jul. 2007, doi: 10.1016/j.diabres.2006.10.015.
[14]
A. J. Garber, R. Ligthelm, J. S. Christiansen, and A. Liebl, ‘Premixed insulin treatment for type 2 diabetes: analogue or human?’, Diabetes, Obesity and Metabolism, vol. 9, no. 5, pp. 630–639, Sep. 2007, doi: 10.1111/j.1463-1326.2006.00654.x.
[15]
S. R. Heller et al., ‘Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes’, Diabetic Medicine, vol. 21, no. 7, pp. 769–775, Jul. 2004, doi: 10.1111/j.1464-5491.2004.01244.x.
[16]
K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, and P. Home, ‘A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes’, Diabetes Care, vol. 29, no. 6, pp. 1269–1274, Jun. 2006, doi: 10.2337/dc05-1365.
[17]
R. R. Holman et al., ‘Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes’, New England Journal of Medicine, vol. 357, no. 17, pp. 1716–1730, Oct. 2007, doi: 10.1056/NEJMoa075392.
[18]
R. R. Holman and R. C. Turner, ‘A Practical Guide to Basal and Prandial Insulin Therapy’, Diabetic Medicine, vol. 2, no. 1, pp. 45–53, Jan. 1985, doi: 10.1111/j.1464-5491.1985.tb00592.x.
[19]
K. Horvath et al., ‘Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD005613.pub3
[20]
S. Mäkimattila, K. Nikkilä, and H. Yki-Järvinen, ‘Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus’, Diabetologia, vol. 42, no. 4, pp. 406–412, Mar. 1999, doi: 10.1007/s001250051172.
[21]
K. Malmberg, ‘Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus’, BMJ, vol. 314, no. 7093, pp. 1512–1512, May 1997, doi: 10.1136/bmj.314.7093.1512.
[22]
F. Ismail-Beigi, ‘Glycemic Management of Type 2 Diabetes Mellitus’, New England Journal of Medicine, vol. 366, no. 14, pp. 1319–1327, Apr. 2012, doi: 10.1056/NEJMcp1013127.
[23]
D. M. Nathan et al., ‘Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, vol. 29, no. 8, pp. 1963–1972, Aug. 2006, doi: 10.2337/dc06-9912.
[24]
M. Marre et al., ‘Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)’, Diabetic Medicine, vol. 26, no. 3, pp. 268–278, Mar. 2009, doi: 10.1111/j.1464-5491.2009.02666.x.
[25]
I. B. Hirsch et al., ‘Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy’, Diabetes, Obesity and Metabolism, vol. 16, no. 3, pp. 206–214, Mar. 2014, doi: 10.1111/dom.12136.
[26]
B. T. Srinivasan and M. Davies, ‘Glycaemic management of type 2 diabetes’, Medicine, vol. 42, no. 12, pp. 711–717, Dec. 2014, doi: 10.1016/j.mpmed.2014.09.011.
[27]
L. A. Young and J. B. Buse, ‘GLP-1 receptor agonists and basal insulin in type 2 diabetes’, The Lancet, vol. 384, no. 9961, pp. 2180–2181, Dec. 2014, doi: 10.1016/S0140-6736(14)61409-4.
[28]
R. M. Bergenstal et al., ‘Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes’, New England Journal of Medicine, vol. 363, no. 4, pp. 311–320, Jul. 2010, doi: 10.1056/NEJMoa1002853.
[29]
M. Diamant et al., ‘Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial’, The Lancet, vol. 375, no. 9733, pp. 2234–2243, Jun. 2010, doi: 10.1016/S0140-6736(10)60406-0.
[30]
S. Gururaj Setty, W. Crasto, J. Jarvis, K. Khunti, and M. J. Davies, ‘New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes’, Postgraduate Medical Journal, vol. 92, no. 1085, pp. 152–164, Mar. 2016, doi: 10.1136/postgradmedj-2015-133716.
[31]
J. Rosenstock et al., ‘Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)’, Diabetes Care, vol. 36, no. 10, pp. 2945–2951, Oct. 2013, doi: 10.2337/dc12-2709.
[32]
J. Bolinder, R. Antuna, P. Geelhoed-Duijvestijn, J. Kröger, and R. Weitgasser, ‘Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial’, The Lancet, vol. 388, no. 10057, pp. 2254–2263, Nov. 2016, doi: 10.1016/S0140-6736(16)31535-5.
[33]
K. Khunti, M. Davies, A. Majeed, B. L. Thorsted, M. L. Wolden, and S. K. Paul, ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’, Diabetes Care, vol. 38, no. 2, pp. 316–322, Feb. 2015, doi: 10.2337/dc14-0920.
[34]
S. E. Inzucchi et al., ‘Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, vol. 38, no. 1, pp. 140–149, Jan. 2015, doi: 10.2337/dc14-2441.
[35]
Z. Z. Htike, F. Zaccardi, D. Papamargaritis, D. R. Webb, K. Khunti, and M. J. Davies, ‘Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis’, Diabetes, Obesity and Metabolism, Feb. 2017, doi: 10.1111/dom.12849.
[36]
M. Evans, P. M. Schumm-Draeger, J. Vora, and A. B. King, ‘A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations’, Diabetes, Obesity and Metabolism, vol. 13, no. 8, pp. 677–684, Aug. 2011, doi: 10.1111/j.1463-1326.2011.01395.x.
[37]
M. Nauck, ‘Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors’, Diabetes, Obesity and Metabolism, vol. 18, no. 3, pp. 203–216, Mar. 2016, doi: 10.1111/dom.12591.
[38]
B. T. Srinivasan, J. Jarvis, K. Khunti, and M. J. Davies, ‘Recent advances in the management of type 2 diabetes mellitus: a review’, Postgraduate Medical Journal, vol. 84, no. 996, pp. 524–531, Oct. 2008, doi: 10.1136/pgmj.2008.067918.
[39]
P. D. Home, ‘The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences’, Diabetes, Obesity and Metabolism, vol. 14, no. 9, pp. 780–788, Sep. 2012, doi: 10.1111/j.1463-1326.2012.01580.x.
[40]
June James, ‘Safety and insulin: implementation of national guidance at a local level’, Journal of diabetes nursing. [Online]. Available: http://le-primo.hosted.exlibrisgroup.com/primo_library/libweb/action/openurl?ctx=&isSerivcesPage=true&rft.jtitle=Journal+of+Diabetes+Nursing&rft.aufirst=June&dscnt=2&url_ctx_fmt=null&vid=44UOLE_services_page&rft.aulast=James&institution=44UOLE&url_ver=Z39.88-2004&rft.atitle=Safety+and+insulin%3A+implementation+of+national+guidance+at+a+local+level&dstmp=1488893669239&fromLogin=true
[41]
P. Rorsman and E. Renstr�m, ‘Insulin granule dynamics in pancreatic beta cells’, Diabetologia, vol. 46, no. 8, pp. 1029–1045, Aug. 2003, doi: 10.1007/s00125-003-1153-1.
[42]
L. Luzi, ‘Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans’, American Journal of Physiology - Endocrinology and Metabolism, vol. 257, no. 2, pp. E241–E246, Aug. 1989 [Online]. Available: http://ajpendo.physiology.org/content/257/2/E241
[43]
Luc JC van Loon, ‘Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate’, The American Journal of Clinical Nutrition, vol. 72, no. 1, pp. 96–105, Jan. 2000 [Online]. Available: http://ajcn.nutrition.org/content/72/1/96.full
[44]
J. G. Menting et al., ‘How insulin engages its primary binding site on the insulin receptor’, Nature, vol. 493, no. 7431, pp. 241–245, Jan. 2013, doi: 10.1038/nature11781.
[45]
J. Wahren and A. Kallas, ‘Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes?’, Diabetes, vol. 61, no. 9, pp. 2228–2229, Sep. 2012, doi: 10.2337/db12-0664.
[46]
B. Richter and G. Neises, ‘“Human” insulin versus animal insulin in people with diabetes mellitus’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD003816.pub2
[47]
W. Crasto et al., ‘Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus’, Postgraduate Medical Journal, vol. 85, no. 1002, pp. 219–222, Apr. 2009, doi: 10.1136/pgmj.2008.073379.
[48]
S. G. Swinnen, A. C. Simon, F. Holleman, J. B. Hoekstra, and J. H. DeVries, ‘Insulin detemir versus insulin glargine for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD006383.pub2
[49]
H. Yki-Järvinen et al., ‘Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study’, Diabetologia, vol. 49, no. 3, pp. 442–451, Mar. 2006, doi: 10.1007/s00125-005-0132-0.
[50]
M. C. Riddle et al., ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin’, Diabetes Care, vol. 36, no. 9, pp. 2489–2496, Sep. 2013, doi: 10.2337/dc12-2454.
[51]
S. C. L. Gough, A. Bhargava, R. Jain, H. Mersebach, S. Rasmussen, and R. M. Bergenstal, ‘Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes’, Diabetes Care, vol. 36, no. 9, pp. 2536–2542, Sep. 2013, doi: 10.2337/dc12-2329.
[52]
I. B. Hirsch et al., ‘Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy’, Diabetes, Obesity and Metabolism, vol. 16, no. 3, pp. 206–214, Mar. 2014, doi: 10.1111/dom.12136.
[53]
B. Zinman et al., ‘Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial’, The Lancet, vol. 377, no. 9769, pp. 924–931, Mar. 2011, doi: 10.1016/S0140-6736(10)62305-7.
[54]
K. Horvath et al., ‘Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD005613.pub3
[55]
J. B. Buse et al., ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’, Annals of Internal Medicine, vol. 154, no. 2, Jan. 2011, doi: 10.7326/0003-4819-154-2-201101180-00300.
[56]
J. Rosenstock et al., ‘Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes’, Diabetes Care, vol. 37, no. 7, pp. 1815–1823, Jul. 2014, doi: 10.2337/dc13-3055.
[57]
C. S. S. Frandsen and S. Madsbad, ‘Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review’, Diabetic Medicine, vol. 31, no. 11, pp. 1293–1300, Nov. 2014, doi: 10.1111/dme.12561.
[58]
I. B. Hirsch, E. Franek, H. Mersebach, L. Bardtrum, and K. Hermansen, ‘Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1)’, Diabetic Medicine, vol. 34, no. 2, pp. 167–173, Feb. 2017, doi: 10.1111/dme.13068.
[59]
H. W. Rodbard et al., ‘Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial’, Diabetic Medicine, vol. 34, no. 2, pp. 189–196, Feb. 2017, doi: 10.1111/dme.13256.
[60]
J. Rosenstock, M. Davies, P. D. Home, J. Larsen, C. Koenen, and G. Schernthaner, ‘A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes’, Diabetologia, vol. 51, no. 3, pp. 408–416, Mar. 2008, doi: 10.1007/s00125-007-0911-x.
[61]
P. Raskin et al., ‘Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs’, Diabetes Care, vol. 28, no. 2, pp. 260–265, Feb. 2005, doi: 10.2337/diacare.28.2.260.
[62]
M. Davies, F. Storms, S. Shutler, M. Bianchi-Biscay, and R. Gomis, ‘Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine’, Diabetes Care, vol. 28, no. 6, pp. 1282–1288, Jun. 2005, doi: 10.2337/diacare.28.6.1282.
[63]
J. C. Pickup, Y. Reznik, and A. J. Sutton, ‘Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials’, Diabetes Care, vol. 40, no. 5, pp. 715–722, May 2017, doi: 10.2337/dc16-2201.
[64]
M. J. Davies et al., ‘Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents’, Diabetes, Obesity and Metabolism, Apr. 2017, doi: 10.1111/dom.12980.
[65]
D. Raccah et al., ‘Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus’, Diabetic Medicine, Jun. 2017, doi: 10.1111/dme.13390.
[66]
S. P. Marso et al., ‘Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes’, New England Journal of Medicine, Jun. 2017, doi: 10.1056/NEJMoa1615692.
[67]
W. Wang, H. Liu, S. Xiao, S. Liu, X. Li, and P. Yu, ‘Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis’, Diabetes Therapy, Jun. 2017, doi: 10.1007/s13300-017-0282-3.
[68]
M. Villani, B. de Courten, and S. Zoungas, ‘Emergency treatment of hypoglycaemia: a guideline and evidence review’, Diabetic Medicine, vol. 34, no. 9, pp. 1205–1211, Sep. 2017, doi: 10.1111/dme.13379.
[69]
L. Leelarathna et al., ‘Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes’, Diabetic Medicine, vol. 34, no. 10, pp. 1372–1379, Oct. 2017, doi: 10.1111/dme.13412.
[70]
‘Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. - PubMed - NCBI’. [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/18715200
[71]
‘New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes’. [Online]. Available: http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/
[72]
B. Anderson, M. Funnell, and American Diabetes Association, The art of empowerment: stories and strategies for diabetes educators, 2nd ed. Alexandria, Va: American Diabetes Association, 2005.
[73]
M. MacKinnon, Providing diabetes care in general practice: a practical guide to integrated care, 4th ed. London: Class, 2002 [Online]. Available: https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=581376
[74]
R. A. Walker, J. Rodgers, and Diabetes UK., Diabetes: a practical guide to managing your health, Fully revised and Updated. London: Dorling Kindersley, 2010.
[75]
‘Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes’. 4AD [Online]. Available: https://www.youtube.com/watch?v=AhhWTmEFuag
[76]
D. Raccah et al., ‘Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus’, Diabetic Medicine, vol. 34, no. 9, pp. 1193–1204, Sep. 2017, doi: 10.1111/dme.13390.
